1. Home
  2. Analysis
  3. Prilosec
  4. Idhifa

Prilosec and Idhifa drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Prilosec (omeprazole) and Idhifa (enasidenib mesylate). Common drug interactions include death among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Prilosec and Idhifa. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Prilosec?

Prilosec has active ingredients of omeprazole. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 175,285 Prilosec users. Check the latest studies of Prilosec.

What is Idhifa?

Idhifa has active ingredients of enasidenib mesylate. eHealthMe is studying from 2,880 Idhifa users. Check the latest studies of Idhifa.

On Jul, 24, 2026

13 people who take Prilosec and Idhifa together, and have interactions are studied.

Prilosec and Idhifa drug interactions.

What are the common drug interactions of Prilosec and Idhifa, by gender? *:

female:

  1. Death
  2. Bone pain
  3. Constipation
  4. Device related infection
  5. Disease progression
  6. Dyspepsia (indigestion)
  7. Nephrolithiasis (calculi in the kidneys)
  8. Pneumonia

male:

  1. Death
  2. Adverse drug reaction
  3. Fall
  4. Head injury
  5. Fatigue (feeling of tiredness)
  6. Nausea (feeling of having an urge to vomit)
  7. Asthenia (weakness)
  8. Blood bilirubin increased
  9. Blood potassium decreased
  10. Cerebral haemorrhage (bleeding within the brain)

What are the common drug interactions of Prilosec and Idhifa, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Death
  2. Asthenia (weakness)
  3. Blood bilirubin increased
  4. Cerebral haemorrhage (bleeding within the brain)
  5. Decreased appetite
  6. Fall
  7. Head injury
  8. Nephrolithiasis (calculi in the kidneys)
  9. Pneumonia

What are the existing conditions these people have? *

  1. Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 6 people, 46.15%
  2. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 2 people, 15.38%
  3. Joint Pain: 2 people, 15.38%
  4. Refractory Anaemia With An Excess Of Blasts (one or more cell types are low in the blood and look abnormal in the bone marrow): 1 person, 7.69%
  5. Neoplasm Malignant (cancer tumour): 1 person, 7.69%
  6. Multiple Myeloma (cancer of the plasma cells): 1 person, 7.69%
  7. Multiple Allergies (allergy to multiple agents): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Prilosec and Idhifa?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Prilosec and Idhifa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Prilosec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Idhifa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Prilosec and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Idhifa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on omeprazole and enasidenib mesylate (the active ingredients of Prilosec and Idhifa, respectively), and Prilosec and Idhifa (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.